Download Files:
CAN508
$42 – $600
Products Details
Product Description
– CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity[1][2].
Web ID
– HY-100429
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C9H10N6O
References
– [1]Krystof V, et al. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006;49(22):6500-6509.|[2]Tong Z, et al. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. Oncotarget. 2017;8(17):28696-28710.
CAS Number
– 140651-18-9
Molecular Weight
– 218.22
Compound Purity
– 99.59
SMILES
– OC1=CC=C(/N=N/C2=C(N)NN=C2N)C=C1
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 250 mg/mL (ultrasonic)
Target
– CDK
Isoform
– CDK1;CDK2;CDK4;CDK7;CDK9
Pathway
– Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
